Australia-wide dispatch

Quantified
Peptides
CJC-1295 NO DAC 10mg — research peptide, lyophilised powder in a glass vial, supplied by Quantified Peptides, Sydney, Australia. For in-vitro research use only.

Peptides

CJC-1295 NO DAC

CJC-1295 without Drug Affinity Complex. Supplied as a lyophilised powder in 10mg vials.

Supplied as lyophilised powder in a 10mg specification. Storage: -20°C · Keep dry, avoid light. Dispatched from Sydney, Australia-wide.

Product information

About CJC-1295 NO DAC

CJC-1295 without Drug Affinity Complex

Research background as published in the scientific literature. Supplied for in-vitro laboratory research only; nothing here is a claim about use in humans or animals.

CJC-1295 NO DAC is a synthetic analogue of growth hormone-releasing hormone (GHRH) that lacks the Drug Affinity Complex (DAC) found in some versions of CJC-1295. The absence of DAC results in a shorter half-life (~30 minutes), producing GH release patterns that more closely mimic endogenous pulsatile secretion.

Research has examined this compound for its ability to stimulate somatotroph cells in the anterior pituitary, with studies investigating downstream effects on IGF-1 levels, body composition parameters, and metabolic markers. It is commonly studied in combination with ghrelin mimetics such as Ipamorelin to target complementary GH release pathways.

Type
GHRH analogue — short acting
Research Areas
Pulsatile GH release, endocrine research
Half-life
~30 minutes
Target
GHRH-R on pituitary somatotrophs
GH Release
Pulsatile — short duration
Often Combined With
Ipamorelin (dual pathway)
IGF-1 Effect
Indirect via GH stimulation
Molecular Weight
~3.3 kDa
  1. 01GHRH Receptor AgonismCJC-1295 NO DAC acts as a growth hormone-releasing hormone (GHRH) analogue, stimulating GHRH-R on pituitary somatotrophs. Research examines how this stimulation influences GH pulse amplitude and frequency in laboratory models.
  2. 02Pulsatile GH ReleaseWithout the Drug Affinity Complex (DAC), this form produces shorter-duration GH stimulation more consistent with natural pulsatile GH release patterns. Research contrasts its pharmacokinetic profile with the DAC-containing version.
  3. 03IGF-1 PathwayResearch has examined downstream effects of CJC-1295 NO DAC on hepatic IGF-1 production, examining the relationship between acute GH pulses and sustained IGF-1 signalling in endocrine research models.

References

  1. 1Teichman SL et al. Prolonged stimulation of GH and IGF-I secretion by CJC-1295. J Clin Endocrinol Metab. 2006;91(3):799-805.
  2. 2Ionescu M, Frohman LA. Pulsatile secretion of growth hormone determines the biological response. J Clin Invest. 2006;116(11):2873-2875.
  3. 3PubMed: pubmed.ncbi.nlm.nih.gov/?term=CJC-1295+GHRH
  4. 4Alba M et al. Once-monthly administration of CJC-1295 in healthy subjects. Horm Res. 2006;66(3):125-130.

Ships from Sydney

Australia-wide, plain unbranded packaging. Dispatched on business days.

If it arrives wrong

Replaced, resent or refunded. You do not have to argue for it.

Also in this range.

Compounds the supplier files alongside this one.

View the range